• 1
    Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22:100718.
  • 2
    Trulock EP, Christie JD, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007; 26:78295.
  • 3
    Hopkins PM, Aboyoun CL, Chhajed PN et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170:10226.
  • 4
    Sharma VK, Bologa RM, Li B et al. Molecular executors of cell death-differential intrarenal expression of Fas ligand, Fas, granzyme B, and perforin during acute and/or chronic rejection of human renal allografts. Transplantation 1996; 62:18606.
  • 5
    Shulzhenko N, Morgun A, Zheng XX et al. Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation. Transplantation 2001; 72:17058.
  • 6
    Shi R, Yang J, Jaramillo A et al. Correlation between interleukin-15 and granzyme B expression and acute lung allograft rejection. Transpl Immunol 2004; 12:1038.
  • 7
    Hodge S, Hodge G, Reynolds PN, Holmes M. Differential rates of apoptosis in BAL and blood of lung transplant patients. J Heart Lung Transplant 2005; 24:130514.
  • 8
    Hodge S, Hodge G, Nairn J, Holmes M, Reynolds PN. Increased airway granzyme b and perforin in current and ex-smoking COPD subjects. COPD 2006; 3:19.
  • 9
    Takayama H, Sitkovsky MV. Antigen receptor-regulated exocytosis in cytotoxic T lymphocytes. J Exp Med 1987; 166:72543.
  • 10
    Froelich CJ, Zhang X, Turbov J et al. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J Immunol 1993; 151:716171.
  • 11
    Estenne M, Maurer JR, Boehler A et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297310.
  • 12
    Stewart S, Fishbein MC, Snell GI et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26:122942.
  • 13
    Hodge S, Hodge G, Holmes M, Reynolds PN. Increased apoptosis in the airways in COPD persists after smoking cessation. Eur Respir J 2005; 25:44754.
  • 14
    Topalidis T, Warnecke H, Müller J, Hetzer R. Endomyocardial biopsies for diagnosis of rejection – the potential margin of error. Transplant Proc 1990; 22:1443.
  • 15
    Sibley RK, Berry GJ, Tazelaar HD et al. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 1993; 12:30824.
  • 16
    Hodge G, Hodge S, Reynolds P, Holmes M. Intracellular cytokines in blood T cells in lung transplant patients – a more relevant indicator of immunosuppression than drug levels. Clin Exp Immunol 2005; 139:15964.
  • 17
    Hodge G, Hodge S, Reynolds P, Holmes M. Increased intracellular pro- and anti-inflammatory cytokines in bronchoalveolar lavage T cells of stable lung transplant patients. Transplantation 2005; 80:10405.
  • 18
    Fantini L, Tomassetti P, Pezzilli R. Management of acute pancreatitis: current knowledge and future perspectives. World J Emerg Surg 2006; 23:116.
  • 19
    Harada N, Okajima K, Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999; 27:20623.
  • 20
    Luh SP, Tsai CC, Shau WY et al. The effects of inhaled nitric oxide, gabexate mesilate, and retrograde flush in the lung graft from non-heart beating minipig donors. Transplantation 2000; 69:201927.